Brief: Bicycle Therapeutics Announces First Patient Dosed In Phase I/II Trial Of Bicycle Tumor-Targeted Immune Cell Agonist Bt7480
04/11/2021 12:56
Nov 4 (Reuters) - Bicycle Therapeutics PLC BCYC.O :
* BICYCLE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE I/II
TRIAL OF BICYCLE® TUMOR-TARGETED IMMUNE CELL AGONIST™ BT7480 IN
PATIENTS WITH ADVANCED SOLID TUMORS ASSOCIATED WITH NECTIN-4
EXPRESSION
Source text for Eikon: ID:nBw884NBNa
Further company coverage: BCYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bicycle Therapeutics
See all newsBicycle Therapeutics Q1 revenue drops after partnership terminations
Brief: Bicycle Therapeutics Announces Oral And Poster Presentations At The Aacr Annual Meeting 2026
UK's Bicycle Therapeutics Q4 revenue jumps, proposes 30% workforce reduction
Brief: Bicycle Therapeutics Says Travis Thompson Appointed As CFO, Succeeds Alethia Young
Bicycle Therapeutics Q3 net loss widens as R&D costs rise